SUPN Supernus Pharmaceuticals Inc

NASDAQ
$28.61

Supernus Pharmaceuticals Inc (SUPN) is expected to report earnings on January 28, 2027, after the market close. The consensus earnings estimate is $0.99 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -32.0% since its last earnings release on October 29, 2026.

Supernus Pharmaceuticals Beat Consensus Estimates, Raises Guidance In-line with Estimates
Thursday, October 29, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Jan 28
Thursday · 4:05 PM ET
Earnings Whisper
-
vs $0.99
Rev est $331.5M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $28.75

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc., is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases.

Sector

Healthcare

Industry

Drug Manufacturers/Other

Charts powered in part by Lightweight Charts™ by TradingView.